The marketing authorisation for Angiox has been withdrawn at the request of the marketing authorisation holder.
Angiox : EPAR - Summary for the public (PDF/544.74 KB)
First published: 02/09/2009
Last updated: 14/09/2018
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
Acute Coronary Syndrome
|Anatomical therapeutic chemical (ATC) code||
The Medicines Company UK Ltd
|Date of issue of marketing authorisation valid throughout the European Union||
115 L Milton Park
25/10/2016 Angiox - EMEA/H/C/000562 - EMEA/H/C/000562/IB/0070
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Angiox is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment-elevation myocardial infarction (STEMI) undergoing primary PCI.
Angiox is also indicated for the treatment of adult patients with unstable angina / non-ST-segment-elevation myocardial infarction (UA / NSTEMI) planned for urgent or early intervention.
Angiox should be administered with aspirin and clopidogrel.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 February 201217/02/2012
European Medicines Agency gives final recommendations for 12 centrally authorised medicines manufactured at Ben Venue Laboratories16/02/2012
European Medicines Agency recommends precautionary recall of remaining batch of Vistide manufactured at Ben Venue Laboratories13/12/2011
European Medicines Agency gives further interim recommendations on dealing with shortcomings in quality assurance at Ben Venue Laboratories09/12/2011
European Medicines Agency gives interim recommendations to deal with shortcomings in quality assurance at Ben Venue Laboratories22/11/2011